7/11/2013

A concentrated mixture of white blood cells has demonstrated an ability to heal persistent wounds of patients suffering from diabetes or restricted blood flow. The treatment, called CureXcell, has a 70% success rate in closing the wounds of 5,000 patients to date, according to its developer, the Israeli company MacroCure. CureXcell is undergoing a Phase III trial in the United States, and the company hopes to have FDA approval by 2017.

Full Story:
Wall Street Daily

Related Summaries